Acquired Hemophilia A Pipeline 2025: Groundbreaking Clinical Advancements by 10+ Global Leaders - DelveInsight | Featuring Pfizer, Novo Nordisk, Hema Biologics, Hoffman-La-Roche, Takeda

DelveInsight's, "Acquired Hemophilia A - Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acquired Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Acquired Hemophilia A reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Acquired Hemophilia A pipeline comprises 10+ pharmaceutical and biotech companies actively developing 10+ therapeutic candidates targeting Acquired Hemophilia A. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.

DelveInsight's "Acquired Hemophilia A Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Acquired Hemophilia A Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Acquired Hemophilia A Drug Development @ https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:

*
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).

*
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.

*
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).

*
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.

*
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.

*
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER Trademark program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.

*
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.

*
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT Trademark study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.

Key Takeaways from the Acquired Hemophilia A Pipeline Report

*
DelveInsight's Acquired Hemophilia A pipeline report highlights a dynamic landscape with over 10 active companies developing more than 10 therapeutic candidates for Acquired Hemophilia A.

*
Qfitlia, approved in March 2025, is the first antithrombin-lowering therapy for routine prophylaxis aimed at preventing or reducing bleeding episodes in patients aged 12 and older with hemophilia A or B, with or without inhibitors.

*
Alhemo, approved in late 2024, is indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B who have inhibitors.

*
Leading companies such as Pfizer, Novo Nordisk, Hema Biologics, Hoffmann-La Roche, Takeda, and others are actively developing new therapies to enhance the treatment landscape for Acquired Hemophilia A.

*
Notable pipeline candidates in various stages of development include Marstacimab, Mim8, Eptacog Beta (LR769), among others.

Acquired Hemophilia A Overview:

Acquired hemophilia A is a rare bleeding disorder that causes unexpected bleeding in people with no prior personal or family history of bleeding problems. It arises when the immune system produces autoantibodies that neutralize clotting factor VIII, often associated with underlying autoimmune conditions. The disorder typically manifests as mucocutaneous bleeding, leading to symptoms such as bruising (ecchymosis), blood in the stool (melena), internal bleeding (hematoma), or blood in the urine (hematuria). Unlike inherited hemophilia A, which is X-linked and mainly affects males, acquired hemophilia A can occur in both men and women.

Download the Acquired Hemophilia A sample report to know in detail about the Acquired Hemophilia A treatment market [https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Acquired Hemophilia A Pipeline Analysis

The Acquired Hemophilia A pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Acquired Hemophilia A Market.

*
Categorizes Acquired Hemophilia A therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Acquired Hemophilia A drugs under development based on:

*
Stage of development

*
Acquired Hemophilia A Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Acquired Hemophilia A Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Acquired Hemophilia A Licensing agreements

*
Funding and investment activities supporting future Acquired Hemophilia A market advancement.

Unlock key insights into emerging Acquired Hemophilia A therapies and market strategies here: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Acquired Hemophilia A Emerging Drugs

Marstacimab - Pfizer

Pfizer has launched a Phase III clinical trial to assess marstacimab, an investigational therapy for patients with severe hemophilia A or B, including those with inhibitors. Marstacimab is an anti-tissue factor pathway inhibitor (anti-TFPI) designed as a prophylactic treatment to help reduce or prevent bleeding episodes.

Mim8 - Novo Nordisk

Mim8, currently in Phase II development, is a next-generation FVIII mimetic designed for subcutaneous prophylactic treatment in hemophilia A patients, including those with or without inhibitors. It is a fully human bispecific antibody that links activated factor IX (FIXa) to factor X (FX).

Eptacog Beta (LR769) - Hema Biologics

Eptacog beta is a recombinant activated factor VII (rFVIIa) therapy currently under FDA evaluation for controlling bleeding episodes in hemophilia A or B patients with inhibitors. Furthermore, two Phase III clinical trials are underway to examine its effectiveness in pediatric patients and surgical scenarios within this population.

Acquired Hemophilia A Pipeline Therapeutic Assessment

Acquired Hemophilia A Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Acquired Hemophilia A By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Acquired Hemophilia A Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Acquired Hemophilia A Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Acquired Hemophilia A therapies and key Acquired Hemophilia A companies [https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Acquired Hemophilia A Current Treatment Patterns

4. Acquired Hemophilia A - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Acquired Hemophilia A Late-Stage Products (Phase-III)

7. Acquired Hemophilia A Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acquired Hemophilia A Discontinued Products

13. Acquired Hemophilia A Product Profiles

14. Acquired Hemophilia A Key Companies

15. Acquired Hemophilia A Key Products

16. Dormant and Discontinued Products

17. Acquired Hemophilia A Unmet Needs

18. Acquired Hemophilia A Future Perspectives

19. Acquired Hemophilia A Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Acquired Hemophilia A pipeline reports offerings [https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acquired-hemophilia-a-pipeline-2025-groundbreaking-clinical-advancements-by-10-global-leaders-delveinsight-featuring-pfizer-novo-nordisk-hema-biologics-hoffmanlaroche-takeda]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.